Core business growth hits over a decade high! Gilead (GILD.US) Q3 delivers "both good and bad news": raises full-year sales guidance, but Biktarvy will face 38% U.S. Medicare price cut pressure

Zhitong Finance APP has learned that U.S. biopharmaceutical giant Gilead Sciences (GILD.US) released its third-quarter 2026 financial report on Thursday, October 29, local time. Driven by double-digit growth in its flagship HIV drug pipeline, the company's product sales for the quarter increased 13% year over year to $8.3 billion, exceeding market expectations; excluding the COVID-19 drug Veklury (remdesivir), "base business" sales increased 16% year over year to $8.2 billion, marking the fastest year-over-year base business growth in more than a decade. Based on the strong results, the company once again raised its full-year sales guidance.